

Innovation all for the patients



Roche A member of the Roche group

Roche Announces the Initiation of a Clinical Study of Chugai's Actemra for the Treatment of COVID-19

TOKYO, March 19, 2020 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced today that Roche issued a press release regarding the initiation of a clinical study of Actemra®/RoActemra®, a humanized anti-human IL-6 receptor monoclonal antibody [generic name: tocilizumab (genetical recombination)] created by Chugai for the treatment of COVID-19.

Please refer to the link below for details of the press release:

Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia

<https://www.roche.com/media/releases/med-cor-2020-03-19.htm>

Trademarks used or mentioned in this release are protected by laws.

###